X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Strides Arcolab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs STRIDES SHASUN LTD - Comparison Results

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA STRIDES SHASUN LTD PLETHICO PHARMA/
STRIDES SHASUN LTD
 
P/E (TTM) x -1.1 44.0 - View Chart
P/BV x 0.0 1.1 1.5% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 PLETHICO PHARMA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
STRIDES SHASUN LTD
Mar-17
PLETHICO PHARMA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs3951,275 31.0%   
Low Rs31918 3.4%   
Sales per share (Unadj.) Rs604.4389.6 155.2%  
Earnings per share (Unadj.) Rs32.528.0 116.1%  
Cash flow per share (Unadj.) Rs51.348.9 105.0%  
Dividends per share (Unadj.) Rs04.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs473.6303.1 156.2%  
Shares outstanding (eoy) m34.0889.42 38.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.42.8 12.5%   
Avg P/E ratio x6.639.2 16.7%  
P/CF ratio (eoy) x4.222.4 18.5%  
Price / Book Value ratio x0.53.6 12.4%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m7,26298,036 7.4%   
No. of employees `000NA5.8 0.0%   
Total wages/salary Rs m1,5965,881 27.1%   
Avg. sales/employee Rs ThNM6,005.9-  
Avg. wages/employee Rs ThNM1,014.0-  
Avg. net profit/employee Rs ThNM431.2-  
INCOME DATA
Net Sales Rs m20,59834,834 59.1%  
Other income Rs m3861,686 22.9%   
Total revenues Rs m20,98436,520 57.5%   
Gross profit Rs m2,8186,428 43.8%  
Depreciation Rs m6421,872 34.3%   
Interest Rs m1,5932,269 70.2%   
Profit before tax Rs m9693,973 24.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m04 0.0%   
Extraordinary Inc (Exp) Rs m0-1,006 0.0%   
Tax Rs m-138470 -29.4%   
Profit after tax Rs m1,1072,501 44.3%  
Gross profit margin %13.718.5 74.1%  
Effective tax rate %-14.311.8 -120.8%   
Net profit margin %5.47.2 74.8%  
BALANCE SHEET DATA
Current assets Rs m18,87738,165 49.5%   
Current liabilities Rs m11,89630,402 39.1%   
Net working cap to sales %33.922.3 152.1%  
Current ratio x1.61.3 126.4%  
Inventory Days Days3677 46.5%  
Debtors Days Days198104 189.4%  
Net fixed assets Rs m9,86137,639 26.2%   
Share capital Rs m341894 38.1%   
"Free" reserves Rs m12,33126,210 47.0%   
Net worth Rs m16,13927,105 59.5%   
Long term debt Rs m4,70616,377 28.7%   
Total assets Rs m33,14681,168 40.8%  
Interest coverage x1.62.8 58.5%   
Debt to equity ratio x0.30.6 48.3%  
Sales to assets ratio x0.60.4 144.8%   
Return on assets %8.15.9 138.6%  
Return on equity %6.99.2 74.3%  
Return on capital %12.312.1 102.0%  
Exports to sales %21.40-   
Imports to sales %15.20-   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136NA-   
Fx inflow Rs m4,40213,465 32.7%   
Fx outflow Rs m3,1844,076 78.1%   
Net fx Rs m1,2199,389 13.0%   
CASH FLOW
From Operations Rs m2,4372,881 84.6%  
From Investments Rs m-6,265-7,051 88.8%  
From Financial Activity Rs m2,4903,382 73.6%  
Net Cashflow Rs m-1,337-788 169.8%  

Share Holding

Indian Promoters % 82.7 27.7 298.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 37.8 11.4%  
FIIs % 5.5 8.6 64.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 25.9 29.0%  
Shareholders   10,665 56,241 19.0%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   SANOFI INDIA  ABBOTT INDIA  FRESENIUS KABI ONCO.  CIPLA  TORRENT PHARMA  

Compare PLETHICO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

STRIDES SHASUN LTD Announces Quarterly Results (4QFY18); Net Profit Down 99.2% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, STRIDES SHASUN LTD has posted a net profit of Rs 8 m (down 99.2% YoY). Sales on the other hand came in at Rs 7 bn (down 25.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA - WYETH LTD COMPARISON

COMPARE PLETHICO PHARMA WITH

MARKET STATS